Affiliation:
1. The Institute for Drug Research The School of Pharmacy The Faculty of Medicine The Hebrew University of Jerusalem Jerusalem 9112001 Israel
2. Department of Biochemistry Molecular and Structural Biology J. Stefan Institute Ljubljana SI‐1000 Slovenia
3. The Institute of Biomedical and Oral Research The Faculty of Dental Medicine The Hebrew University of Jerusalem Jerusalem 9112001 Israel
4. Department of Prosthodontics The Faculty of Dental Medicine The Hebrew University of Jerusalem Jerusalem 9112001 Israel
5. Department of Cardiothoracic Surgery Hadassah Hebrew University Medical Center The Faculty of Medicine The Hebrew University of Jerusalem Jerusalem 9112001 Israel
Abstract
AbstractCathepsin‐K (CTSK) is an osteoclast‐secreted cysteine protease that efficiently cleaves extracellular matrices and promotes bone homeostasis and remodeling, making it an excellent therapeutic target. Detection of CTSK activity in complex biological samples using tailored tools such as activity‐based probes (ABPs) will aid tremendously in drug development. Here, potent and selective CTSK probes are designed and created, comparing irreversible and reversible covalent ABPs with improved recognition components and electrophiles. The newly developed CTSK ABPs precisely detect active CTSK in mouse and human cells and tissues, from diseased and healthy states such as inflamed tooth implants, osteoclasts, and lung samples, indicating changes in CTSK's activity in the pathological samples. These probes are used to study how acidic pH stimulates mature CTSK activation, specifically, its transition from pro‐form to mature form. Furthermore, this study reveals for the first time, why intact cells and cell lysate exhibit diverse CTSK activity while having equal levels of mature CTSK enzyme. Interestingly, these tools enabled the discovery of active CTSK in human osteoclast nuclei and in the nucleoli. Altogether, these novel probes are excellent research tools and can be applied in vivo to examine CTSK activity and inhibition in diverse diseases without immunogenicity hazards.
Funder
Israel Science Foundation
Teva Pharmaceutical Industries